Humacyte, Inc. entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC to issue and sell 47,619,048 shares of common stock at $1.05 per share. The company expects to receive net proceeds of approximately $46.80 million, or approximately $53.85 million if the underwriters' 30-day option to purchase an additional 7,142,857 shares is exercised in full. The offering is expected to close on or about June 12, 2026. Humacyte, Inc. is a biotechnology company developing human-made tissue engineering products.
